Acute Porphyria Drug Database

A16AX05 - Zinc Acetate
Not porphyrinogenic
NP

Rationale
There is no data indicating zinc acetate is interacting with CYP and it is therefore probably not porphyrinogenic.
Chemical description
Zinc salt
Therapeutic characteristics
Zinc acetate is indicated for the treatment of Wilson’s disease.
Metabolism and pharmacokinetics
Around 80% of zinc is bound to erythrocytes and the rest is mainly bound to albumin and other plasma proteins. The elimination of zinc results primarily from faecal excretion. The faecal excretion is in the greatest part due to the passage of unabsorbed zinc but it is also due to endogenous intestinal secretion.

References

  1. Summary of Product Characteristics
  2. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). zinc acetate. #1145

Similar drugs
Explore alternative drugs in similar therapeutic classes A16A / A16AX or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙